Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM)

The Patient Registry of Intrathecal Ziconotide Management (PRIZM) evaluated long‐term effectiveness, safety, and tolerability of intrathecal ziconotide treatment in clinical practice.

[1]  J. Pilitsis,et al.  Use of Low Dose Ziconotide as First‐Line Intrathecal Monotherapy , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[2]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[3]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[4]  D. Monnin,et al.  Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. , 2011, Pain physician.

[5]  Jörn Lötsch,et al.  Ziconotide for treatment of severe chronic pain , 2010, The Lancet.

[6]  M. Wallace,et al.  Current Developments in Intraspinal Agents for Cancer and Noncancer Pain , 2010, Current pain and headache reports.

[7]  G. Varrassi,et al.  Intrathecal Therapy: What Has Changed With the Introduction of Ziconotide , 2009, Pain practice : the official journal of World Institute of Pain.

[8]  T. Deer,et al.  Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study. , 2009, Pain physician.

[9]  J. McGivern.  Ziconotide: a review of its pharmacology and use in the treatment of pain , 2007, Neuropsychiatric disease and treatment.

[10]  L. Webster,et al.  A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. , 2006, Journal of pain and symptom management.

[11]  M. Byas-Smith,et al.  Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[12]  M. Byas-Smith,et al.  Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. , 2004, JAMA.

[13]  W. Raffaeli,et al.  Italian registry on long-term intrathecal ziconotide treatment. , 2011, Pain physician.